Vaxcyte (PCVX) Other Working Capital Changes (2019 - 2026)

Vaxcyte (PCVX) has reported Other Working Capital Changes for 3 consecutive years, with -$1.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Working Capital Changes fell 108.03% year-over-year to -$1.3 million; the TTM figure through Mar 2026 stood at $29.1 million (down 51.27% YoY), while the FY2025 annual figure was $46.4 million, up 10.71% from the prior year.
• Other Working Capital Changes retreated to -$1.3 million in Q1 2026 per PCVX's latest filing, from $33.1 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $24.0 million in Q4 2024 and bottomed at -$16.5 million in Q4 2023.
• Historically, Other Working Capital Changes has averaged $2.5 million across 5 years, with a median of $1.6 million in 2022.
• On a YoY basis, Other Working Capital Changes climbed as much as 986.86% in 2025 and fell as far as 158.92% in 2025.
• Vaxcyte's Other Working Capital Changes stood at $43.2 million in 2024, then declined by 23.21% to $33.1 million in 2025, then tumbled by 103.88% to -$1.3 million in 2026.
• Business Quant data shows PCVX's Other Working Capital Changes at -$1.3 million in Q1 2026, $33.1 million in Q4 2025, and -$1.4 million in Q3 2025.